JP2005533870A - アバカビールおよびアロブジンの相乗的相互作用 - Google Patents
アバカビールおよびアロブジンの相乗的相互作用 Download PDFInfo
- Publication number
- JP2005533870A JP2005533870A JP2004548906A JP2004548906A JP2005533870A JP 2005533870 A JP2005533870 A JP 2005533870A JP 2004548906 A JP2004548906 A JP 2004548906A JP 2004548906 A JP2004548906 A JP 2004548906A JP 2005533870 A JP2005533870 A JP 2005533870A
- Authority
- JP
- Japan
- Prior art keywords
- beer
- alobudine
- abaca
- alovudine
- combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
Description
実施例1:臨床試験
現行のNRTIを含む処方で失敗した15人の患者にフェーズIIaの臨床試験を行った。各患者は>1000cp/mlのHIV RNAを有しており、遺伝子型アッセイで確立されたところにより、以前のウイルス療法で誘発されたウイルスRT中の少なくとも2つの突然変異を有していた。患者は3.93log10 cp/mlのベースラインウイルス量(viral load)を有していた。
MT4細胞でのHIV−1複製に対する他のNRTIと組み合わせたMIV−310の抗ウイルス作用を半効果法(median effect method)(ChaoおよびTalalay 1983)により調べた。アッセイは、各ウエルに105の細胞および20〜50組織培養感染量(tissue culture infective doses)のHIV−1、IIIbを入れたマイクロタイタープレートで行った。各薬剤単独および一定比の薬剤の混合物を2倍段階で系列希釈し、ウエルに4つずつ加えた。この一定比は、薬剤の相対的な効力を反映するように選択する。たとえば、細胞培養でのアバカビールの効力はアロブジンの効力よりも200倍低い。従って、混合物を等モルにするなら、アバカビールの混合物内での相対的な寄与はアロブジンの効力によって掻き消されてしまうであろう。1:200アバカビール:アロブジンの比にて、これら2つの薬剤のそれぞれの寄与が明らかとなり、相乗作用によって付加された活性を測定することができる。抗ウイルス作用は第5日目にXTT比色法を用いて測定した。
DA/DxA+DB/DxB+α(DADB)/(DxADxB)
(式中、DxAは化合物A単独での所定の作用をもたらす濃度、DAは同じ抑制をもたらす混合物中の化合物Aの濃度、DxBおよびDBは化合物Bについて同様の意味を有し、アルファは各成分が相互に排他的であるときに0または相互に排他的であるときに1である)。
Claims (11)
- アバカビールとアロブジンとの相乗作用を生じる組み合わせおよび薬理学的に許容しうる担体を含む医薬製剤。
- アロブジンが単位投与量当たり1〜10mgの量で含まれる、請求項1に記載の医薬製剤。
- アロブジンが単位投与量当たり0.5〜7.5mgの量で含まれる、請求項2に記載の医薬製剤。
- アロブジンが単位投与量当たり0.5〜5mgの量で含まれる、請求項3に記載の医薬製剤。
- アバカビールが単位投与量当たり200〜800mgの量で含まれる、請求項1に記載の医薬製剤。
- アバカビールが単位投与量当たり300〜500mgの量で含まれる、請求項5に記載の医薬製剤。
- アロブジンおよびアバカビールが、それぞれのED50に対応した重量比で含まれる、請求項1に記載の医薬製剤。
- アロブジンおよびアバカビールが、1〜10:200〜800の比で含まれる、請求項1に記載の医薬製剤。
- アロブジンおよび/またはアバカビール、およびアロブジンとアバカビールとの両者を組み合わせて使用するに際しての説明書を含む情報インサートを含む患者パック。
- 多剤耐性HIVの治療のためのアロブジンとアバカビールとの組み合わせての使用であって、アロブジンとアバカビールとを同時に、組み合わせてまたは連続して投与することを含む使用。
- 請求項1ないし8のいずれか一つに記載の医薬製剤の投与または請求項9に記載の患者パックを含む、請求項10に記載の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0202022A SE0202022D0 (sv) | 2002-06-27 | 2002-06-27 | Synergistic interaction of abacavir and alovudine |
EP02024744 | 2002-11-06 | ||
PCT/SE2003/001100 WO2004002433A1 (en) | 2002-06-27 | 2003-06-24 | Synergistic interaction of abacavir and alovudine |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2005533870A true JP2005533870A (ja) | 2005-11-10 |
Family
ID=30001852
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004548906A Pending JP2005533870A (ja) | 2002-06-27 | 2003-06-24 | アバカビールおよびアロブジンの相乗的相互作用 |
Country Status (19)
Country | Link |
---|---|
US (1) | US20060084627A1 (ja) |
EP (1) | EP1536800B1 (ja) |
JP (1) | JP2005533870A (ja) |
KR (1) | KR20050013628A (ja) |
CN (1) | CN1302779C (ja) |
AT (1) | ATE314851T1 (ja) |
AU (1) | AU2003239088B2 (ja) |
BR (1) | BR0311141A (ja) |
CA (1) | CA2481890A1 (ja) |
DE (1) | DE60303131T2 (ja) |
ES (1) | ES2254941T3 (ja) |
HK (1) | HK1079981B (ja) |
IL (1) | IL164921A0 (ja) |
MX (1) | MXPA04012754A (ja) |
NO (1) | NO20050445L (ja) |
NZ (1) | NZ535817A (ja) |
PL (1) | PL373758A1 (ja) |
RU (1) | RU2320347C2 (ja) |
WO (1) | WO2004002433A1 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1610797A1 (en) * | 2003-03-27 | 2006-01-04 | Boehringer Ingelheim International GmbH | Antiviral combination of nevirapine and a further antiretroviral compound |
GB0608876D0 (en) | 2006-05-05 | 2006-06-14 | Medivir Ab | Combination therapy |
MX367937B (es) * | 2010-01-27 | 2019-09-12 | Viiv Healthcare Co | Combinaciones de compuestos que comprenden inhibidores de la integrasa de vih y otros agentes terapéuticos. |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04506961A (ja) * | 1989-07-19 | 1992-12-03 | ハーメンベルイ,ヨハン | 抗ウイルス組成物 |
WO2000009531A2 (en) * | 1998-08-10 | 2000-02-24 | Novirio Pharmaceuticals Limited | β-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B |
WO2000016779A1 (en) * | 1998-09-18 | 2000-03-30 | Glaxo Group Limited | Antiviral combinations comprising lamivudine and abacavir |
WO2000043014A2 (en) * | 1999-01-22 | 2000-07-27 | Emory University | Beta-d-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine for use in the treatment of hiv infections |
WO2001093898A1 (en) * | 2000-06-02 | 2001-12-13 | Smithkline Beecham Corporation | Methods of treating viral diseases with il-18 and il-18 combinations |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE8602981D0 (sv) * | 1986-07-04 | 1986-07-04 | Astra Laekemedel Ab | Novel medicinal use |
US5446029A (en) * | 1986-07-04 | 1995-08-29 | Medivir Ab | Anti-retroviral activity of 2',3'-dideoxy-3'-fluoronucleosides |
GB8719877D0 (en) * | 1987-08-22 | 1987-09-30 | Wellcome Found | Antiviral compounds |
NZ229453A (en) * | 1988-06-10 | 1991-08-27 | Univ Minnesota & Southern Rese | A pharmaceutical composition containing purine derivatives with nucleosides such as azt, as antiviral agents |
MY104575A (en) * | 1989-12-22 | 1994-04-30 | The Wellcome Foundation Ltd | Therapeutic nucleosides. |
US6514979B1 (en) * | 1999-03-03 | 2003-02-04 | University Of Maryland Biotechnology Institute | Synergistic combinations of guanosine analog reverse transcriptase inhibitors and inosine monophosphate dehydrogenese inhibitors and uses therefor |
-
2003
- 2003-06-24 DE DE60303131T patent/DE60303131T2/de not_active Expired - Fee Related
- 2003-06-24 ES ES03733801T patent/ES2254941T3/es not_active Expired - Lifetime
- 2003-06-24 CN CNB038151685A patent/CN1302779C/zh not_active Expired - Fee Related
- 2003-06-24 NZ NZ535817A patent/NZ535817A/en not_active IP Right Cessation
- 2003-06-24 MX MXPA04012754A patent/MXPA04012754A/es active IP Right Grant
- 2003-06-24 JP JP2004548906A patent/JP2005533870A/ja active Pending
- 2003-06-24 US US10/519,332 patent/US20060084627A1/en not_active Abandoned
- 2003-06-24 BR BR0311141-5A patent/BR0311141A/pt not_active IP Right Cessation
- 2003-06-24 KR KR10-2004-7021155A patent/KR20050013628A/ko not_active Application Discontinuation
- 2003-06-24 WO PCT/SE2003/001100 patent/WO2004002433A1/en active IP Right Grant
- 2003-06-24 EP EP03733801A patent/EP1536800B1/en not_active Expired - Lifetime
- 2003-06-24 AT AT03733801T patent/ATE314851T1/de not_active IP Right Cessation
- 2003-06-24 AU AU2003239088A patent/AU2003239088B2/en not_active Ceased
- 2003-06-24 CA CA002481890A patent/CA2481890A1/en not_active Abandoned
- 2003-06-24 RU RU2005101874/15A patent/RU2320347C2/ru not_active IP Right Cessation
- 2003-06-24 PL PL03373758A patent/PL373758A1/xx not_active Application Discontinuation
-
2004
- 2004-10-28 IL IL16492104A patent/IL164921A0/xx unknown
-
2005
- 2005-01-26 NO NO20050445A patent/NO20050445L/no not_active Application Discontinuation
-
2006
- 2006-01-03 HK HK06100011.9A patent/HK1079981B/zh not_active IP Right Cessation
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04506961A (ja) * | 1989-07-19 | 1992-12-03 | ハーメンベルイ,ヨハン | 抗ウイルス組成物 |
WO2000009531A2 (en) * | 1998-08-10 | 2000-02-24 | Novirio Pharmaceuticals Limited | β-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B |
WO2000016779A1 (en) * | 1998-09-18 | 2000-03-30 | Glaxo Group Limited | Antiviral combinations comprising lamivudine and abacavir |
WO2000043014A2 (en) * | 1999-01-22 | 2000-07-27 | Emory University | Beta-d-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine for use in the treatment of hiv infections |
WO2001093898A1 (en) * | 2000-06-02 | 2001-12-13 | Smithkline Beecham Corporation | Methods of treating viral diseases with il-18 and il-18 combinations |
Also Published As
Publication number | Publication date |
---|---|
ES2254941T3 (es) | 2006-06-16 |
EP1536800A1 (en) | 2005-06-08 |
WO2004002433A8 (en) | 2004-05-06 |
CN1302779C (zh) | 2007-03-07 |
KR20050013628A (ko) | 2005-02-04 |
AU2003239088B2 (en) | 2006-11-02 |
ATE314851T1 (de) | 2006-02-15 |
RU2320347C2 (ru) | 2008-03-27 |
WO2004002433A1 (en) | 2004-01-08 |
HK1079981A1 (en) | 2006-04-21 |
IL164921A0 (en) | 2005-12-18 |
CN1665509A (zh) | 2005-09-07 |
HK1079981B (zh) | 2007-10-12 |
BR0311141A (pt) | 2005-06-07 |
EP1536800B1 (en) | 2006-01-04 |
DE60303131T2 (de) | 2006-07-20 |
RU2005101874A (ru) | 2005-06-27 |
DE60303131D1 (de) | 2006-03-30 |
MXPA04012754A (es) | 2005-03-23 |
NZ535817A (en) | 2006-11-30 |
US20060084627A1 (en) | 2006-04-20 |
AU2003239088A1 (en) | 2004-01-19 |
CA2481890A1 (en) | 2004-01-08 |
NO20050445L (no) | 2005-01-26 |
PL373758A1 (en) | 2005-09-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101524165B1 (ko) | Hiv 인테그라제 억제제의 약동학을 개선하기 위한 방법 | |
US20060069155A1 (en) | Method for reducing exacerbations associated with COPD | |
JP2016138142A (ja) | 大うつ病を有する患者において減量療法を提供する方法 | |
KR20050044587A (ko) | B형 간염 바이러스 감염 치료용 포스포네이트뉴클레오타이드 유사체의 용도 | |
JP2011079840A (ja) | B型肝炎治療のための組合せ療法 | |
JPS63243028A (ja) | 基本的うつ病を軽減するためのうつ病治療剤 | |
CA2450915C (en) | Use of levosimendan and beta-adrenergic receptor antagonist for the treatment of heart failure | |
JP2005533870A (ja) | アバカビールおよびアロブジンの相乗的相互作用 | |
JPH03170475A (ja) | 抑うつ症治療剤 | |
JP2004505039A (ja) | Copdに付随する増悪の減少方法 | |
JP2701042B2 (ja) | 抗鬱病剤作用を有する新規な結合生成物 | |
JP2003513888A (ja) | 神経疾患治療用医薬品 | |
KR102405447B1 (ko) | 5-(2-아마노에틸)-디벤조[cd,f]-인돌-4(5H)-온 유도체 화합물, 이의 제조방법 및 이를 유효성분으로 포함하는 항 HIV-1용 약학적 조성물 | |
KR101971762B1 (ko) | 성기능장애의 치료에 사용하기 위한 a3 아데노신 수용체 리간드 | |
JP5800485B2 (ja) | 鼻汁分泌抑制用組成物 | |
ZA200409147B (en) | A combination of an NMDA-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease | |
JPH08502044A (ja) | ヒトウイルス感染の治療 | |
WO2004002498A1 (en) | Antiviral regimens | |
JPH06211657A (ja) | 尿酸排泄剤 | |
JPH0692303B2 (ja) | 恐慌障害の軽減に対するゲピロン | |
JPH09188623A (ja) | レトロウイルス感染治療剤 | |
JPH07188004A (ja) | 感冒薬 | |
WO2015001358A1 (en) | Drug combination and its use in therapy of obesity and type ii diabetes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060427 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20091104 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100129 |
|
RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20100204 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20100204 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100316 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100810 |